nCounter® Metabolic Pathways Panel

Helping Your Research

Quantify the expression of hundreds of genes involved in core metabolic processes and immunometabolism for human or mouse samples in a reliable, simple, and robust way using the nCounter Metabolic Pathways Panel. Understand the complex mechanisms behind metabolic adaptation, metabolic switching, metabolic alterations, and study changes in mitochondrial respiration and glycolysis.

The Metabolic Pathways Panel helps advance efforts towards novel therapeutic targets that take advantage of altered metabolism in cancer and other diseases. Get results in less than 24 hours from multiple sample types with a workflow that maximizes insight and minimizes turnaround time:

Quantify the presence and relative abundance of 14 different immune cell types for immunometabolism studies
Bypass RT and amplification by direct detection, yielding highly reproducible data
Process your samples with < 30 minutes hands-on time and get results in < 24 hours
Receive publication-ready figures with off-the-shelf data analysis with nSolver™ Data Analysis Software

How It Works

The underlying molecular mechanisms behind alterations in metabolic pathways, signaling pathways, and cell stress can now be fully elucidated, giving you a complementary tool to traditional metabolite assays for profiling metabolic checkpoints and potential therapeutic targets.

Directly profile 768 genes in human or mouse across 34 annotated pathways involved in five important themes for metabolism research:

01:

Biosynthesis and Anabolic Pathways

02:

Nutrient Capture and Catabolic Pathways

03:

Cell Stress

04:

Metabolic Signaling

05:

Transcriptional Regulation

Publications

View All Publications

A novel diagnostic approach for the classification of small B-cell lymphoid neoplasms based on the NanoString platform.

Small B-cell lymphoid neoplasms (SBCLNs) are a heterogeneous group of diseases characterized by malignant clonal proliferation of mature B-cells. However, the classification of SBCLNs remains a challenge, especially in cases where histopathological analysis is unavailable or those with atypical laboratory findings or equivocal pathologic data.

Remodeling of the tumor microenvironment via disrupting Blimp1(+) effector Treg activity augments response to anti-PD-1 blockade.

BACKGROUND: Accumulation of Foxp3(+) regulatory T (Treg) cells in the tumor often represents an important mechanism for cancer immune evasion and a critical barrier to anti-tumor immunity and immunotherapy. Many tumor-infiltrating Treg cells display an activated phenotype and express the transcription factor Blimp1.

Expression of CIB1 correlates with colorectal liver metastases but not with peritoneal carcinomatosis.

Background: Molecular differences in colorectal cancer (CRC) are associated with the metastatic route. Patient survival is mainly driven by metastatic spread thus it is imperative to understand its key drivers to develop biomarkers for risk stratification, follow-up protocols and personalized therapy.